Article Sidebar

PDF
Date Published: 11/12/2023
Abstract Views: 369
Views PDF: 101
DOI: https://doi.org/10.51298/vmj.v532i2.7522
Issue
Vol. 532 No. 2 (2023)
Section
Các bài báo
How to Cite
Hoàng , Đình Âu, & Trương , T. T. . (2023). EVALUATION OF LESIONS SCORING ≥3 OF PROSTATE TRANSITION ZONE ACCORDING TO PI-RADS V2.1 TO DETECT CANCER WITH GLEASON SCORE ≥7. Vietnam Medical Journal, 532(2). https://doi.org/10.51298/vmj.v532i2.7522

EVALUATION OF LESIONS SCORING ≥3 OF PROSTATE TRANSITION ZONE ACCORDING TO PI-RADS V2.1 TO DETECT CANCER WITH GLEASON SCORE ≥7

Đình Âu Hoàng 1,, Thị Thanh Trương 1
1 HMU hospital

Main Article Content

Abstract

Purpose: To evaluate the diagnostic accuracy of lesions with PI-RADS score ≥ 3 according to the PI-RADS v2.1 classification to detect transition zone prostate cancer GS ≥7, based on the histopathological results of biopsy under transrectal ultrasound guided. Material and methods: Retrospective study from a database of 67 patients undergoing prostate MRI and biopsies under transrectal ultrasound guided in a continuous period from February 2019 to May 2022. Two radiologists blinded with histopathology independently evaluated T2-weighted images, DWI, ADC maps, and dynamic contrast enhancement sequences according to the PI-RADS version 2.1 classification. Lesions with a PI-RADS score ≥ 3 of the transition zone will be compared with histopathology based on prostate sectors. Two groups of cancer lesions with Gleason scores ≤6 and ≥7 will be analyzed separately. Then evaluate the performance of PI-RADS version 2.1 in detecting cancer with Gleason score ≥7 for lesions with a PI-RADS score ≥ 3. Result: Assessment by PI-RADS v2.1, there were 65 lesions with PI-RADS score ≥ 3 out of 67 patients in the study, in which the number of lesions with PI-RADS score of 3, 4, 5 were 27, 13 and 25, respectively. Biopsy results under transrectal ultrasound guided of these lesions showed 32 cancerous lesions, accounting for 49% and 33 non-cancerous lesions, accounting for 51%. Among 32 cancer lesions, there are 7 cancers with Gleason score ≤6, accounting for 22% and 25 cancers with Gleason score ≥ 3+4, accounting for 78%. The overall number of cancers for lesions score 3, 4, 5 were 3, 6 and 23, respectively. The number of cancers with Gleason score ≥ 7 for lesions score 3, 4, 5 were 2, 2, and 21, respectively. The cancer detection performance of PIRADS v2.1 for lesions PI-RADS score ≥ 3 was 0.76. With a cut-off score ≥4, the sensitivity and specificity of PI-RADS v2.1 for cancer GS ≥ 7 detection in transition zone for lesions PI-RADS scores ≥ 3 were 84% and 71%, respectively. Lesions PI-RADS score 5 had a sensitivity of 84% for cancer of Gleason score ≥ 7 detection.

Article Details

Keywords

PI-RADS classification version 2.1, cancer Gleason score ≥7, prostate transition zone.

References

1. Weinreb JC, Barentsz JO, Choyke PL, et al. (2016) PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol. 69(1):16–40
2. American College of Radiology. MR Prostate Imaging Reporting and Data System version 2.0. http://www.acr.org/Quality-Safety/ Resources/PIRADS/. Accessed 15 Jan 2017
3. Fulgham PF, Rukstalis DB, Turkbey IB, et al. (2017) AUA policy statement on the use of multiparametric magnetic resonance imaging in the diagnosis, staging and management of prostate cancer. J Urol. 198(4):832–838
4. Rosenkrantz AB, Kim S, Campbell N, Gaing B, Deng F-M, Taneja SS. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. American Journal of Roentgenology. 2015 ;204(3): W266-W272.
5. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. European urology. 2019;76(3):340-351.
6. Grey ADR, Chana MS, Popert R, et al. (2015) Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting. BJU Int. 115(5):728–735
7. Arumainayagam N, Ahmed HU, Moore CM, et al. (2013) Multi- parametric MR imaging for detection of clinically significant prostate cancer: a validation Cohort Study with transperineal template prostate mapping as the reference standard. Radiology 268(3):761–769
8. Seo JW, Shin S-J, Taik OhY, et al. (2017) PI-RADS version 2: detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer. AJR Am J Roentgenol. 209(1):W1– W9.
9. Vargas HA, Ho ̈ tker AM, Goldman DA, et al. (2016) Updated prostate imaging reporting and data system (PIRADS v2) recom- mendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 26:1606. https://doi. org/10.1007/s00330-015-4015-6
10. Muller BG, Shih JH, Sankineni S, et al. Prostate cancer: interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multipara- metric MR imaging. Radiology 2015;277(3):741–750.